Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nilotinib in chronic GVHD after Imatinib failure
NCT02891395Phase 2Completed
- Sponsor
- CHU de Lille
- Start
- Dec 2012
- Primary completion
- Jul 2017
- Modality
- Small Molecules
- Countries
- 2
01
Overview
A Phase 2 trial of nilotinib in graft-versus-host disease (GVHD), sponsored by CHU de Lille. Started Dec 2012; status: completed.
02
Drugs
nilotinib
03
Conditions
graft-versus-host disease (GVHD)
Beyond the preview
Go deeper on NCT02891395.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02891395.